Latest Breaking News On - Byoung chol cho - Page 1 : comparemela.com

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Byoung chol choYonsei university college of medicineYonsei cancer centerDivision of medical oncologyMedical oncologyYonsei university college